Nippon Shinyaku Co., Ltd. (TYO: 4516)
Japan
· Delayed Price · Currency is JPY 3,986.00
-31.00 (-0.77%)
Nov 13, 2024, 3:45 PM JST
Nippon Shinyaku Revenue
Nippon Shinyaku had revenue of 39.13B JPY in the quarter ending June 30, 2024, with 5.73% growth. This brings the company's revenue in the last twelve months to 150.37B, up 3.30% year-over-year. In the fiscal year ending March 31, 2024, Nippon Shinyaku had annual revenue of 148.26B with 2.83% growth.
Revenue (ttm)
150.37B
Revenue Growth
+3.30%
P/S Ratio
1.80
Revenue / Employee
67.95M
Employees
2,213
Market Cap
270.29B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2024 | 148.26B | 4.08B | 2.83% |
| Mar 31, 2023 | 144.18B | 6.69B | 4.87% |
| Mar 31, 2022 | 137.48B | 15.60B | 12.80% |
| Mar 31, 2021 | 121.89B | 5.25B | 4.50% |
| Mar 31, 2020 | 116.64B | 1.92B | 1.67% |
| Mar 31, 2019 | Pro | Pro | Pro |
| Mar 31, 2018 | Pro | Pro | Pro |
| Mar 31, 2017 | Pro | Pro | Pro |
| Mar 31, 2016 | Pro | Pro | Pro |
| Mar 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionNippon Shinyaku News
- 7 weeks ago - Week In Review: Nippon Shinyaku Signs $735m Deal For DMD Therapy - Seeking Alpha
- 2 months ago - Capricor Therapeutics partners with Nippon Shinyaku for European commercialization of Deramiocel - Seeking Alpha
- 2 months ago - EXCLUSIVE: Capricor Therapeutics Inks European Expansion, Commercialization Pact For Lead Asset With Japanese Pharma Firm - Benzinga